DM Corporation and ORF Genetics to Collaborate on Protein Drugs
An MOU Signed During Official Visit of Mrs. Preneet Kau, Indian Minister of State for External Affairs, to Iceland
The MOU states that the companies will form a joint venture to develop and market human recombinant therapeutic proteins and biosimilars. DM Corporation will bring to the collaboration expertise in management of pre-clinical research, clinical development and marketing. ORF Genetics will supply its expertise in plant genetics and protein biochemistry, including its proprietary Orfeus(TM) protein production system in genetically modified barley. The Orfeus (TM) platform was developed to produce high-quality recombinant proteins on a large scale, bypassing production in E. coli, yeast or mammalian cells.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.